Wobble Genomics Unveils Innovative Liquid Biopsy Technology at ESMO 2025

In a groundbreaking presentation at the European Society for Medical Oncology (ESMO) 2025 Congress held from October 17-21, Wobble Genomics revealed new findings that highlight the robustness of their advanced liquid biopsy platform. This innovative technology is designed for the sensitive detection of low-abundance RNA, marking a significant step forward in cancer diagnostics and treatment.

Wobble Genomics, a leading biotechnology firm, is committed to improving cancer patient outcomes through better diagnostic methods and therapy selection. The company’s latest data presentation focused on a novel ultra-sensitive cell-free RNA (cfRNA) liquid biopsy diagnostic platform. Dr. Richard Kuo, the company’s CEO and founder, emphasized the importance of this technology in transforming cancer treatment protocols. “Our new platforms mark a major breakthrough in liquid biopsy technology,” Dr. Kuo stated. He noted that the advancements allow for highly sensitive and accurate detection of cancer transcripts from whole blood samples, which can lead to more effective cancer treatments.

Key Findings

The poster presentation, titled Analytical Performance of a Novel Long-Read RNA Sequencing Assay for Low-Abundance Cancer Transcript Detection from Whole Blood, showcased the analytical robustness of a long-read RNA sequencing assay. This assay enables the detection of low-abundance RNA across a broad spectrum of RNA sizes, making it a versatile tool for researchers and clinicians alike. During the study, the method identified novel isoforms of prominent cancer genes, particularly HER2 and TROP2, in blood samples from patients with cancer. This discovery is crucial as it opens new avenues for the development of antibody-drug conjugates (ADCs) and enhances patient stratification for more precise and personalized treatment options.

A Leap Forward in Liquid Biopsy Technology

The long-read sequencing approach demonstrated not only the feasibility of detecting low-abundance RNA in the bloodstream but also its potential in improving cancer diagnostics. Current methodologies often struggle with low-abundance transcripts, leading to missed opportunities for early detection and treatment. However, Wobble Genomics' advancements aim to address these challenges, providing healthcare providers with powerful tools to diagnose and monitor cancer more effectively.

Dr. Kuo reiterated the significance of these findings, indicating that they pave the way for establishing a reliable diagnostic tool. “The promising data shared today represents an important step towards establishing an effective diagnostic tool,” he explained, highlighting how this could transform the approach to cancer treatment.

Background on Wobble Genomics

Founded in Edinburgh at The Roslin Institute, Wobble Genomics is pioneering advancements in the field of cancer diagnostics. The company’s innovative focus on cfRNA liquid biopsy diagnostics represents a shift toward understanding and treating cancer and other diseases in a novel manner. With a team of experts in genomics, diagnostics, and oncology, Wobble Genomics is advancing the science of liquid biopsies, and currently collaborating with the National Health Service (NHS) in the UK to conduct further clinical studies.

As Wobble Genomics continues to push the boundaries of cancer diagnostics, they invite industry stakeholders, researchers, and healthcare professionals to explore their work further. For more information about their innovative solutions, visit Wobble Genomics’ website and follow them on LinkedIn.

Conclusion

The developments presented at the ESMO 2025 Congress underline the transformative potential of liquid biopsy technologies in oncology. As Wobble Genomics continues to innovate in this space, the future of cancer diagnostics and treatment looks promising, with improved accuracy and accessibility poised to change the landscape for patients worldwide.